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Low and middle income countries (LMICs) bear a huge,
disproportionate and growing burden of cardiovascular
disease (CVD) which constitutes a threat to
development. Efforts to tackle the global burden of CVD
must therefore emphasise effective control in LMICs by
addressing the challenge of scarce resources and lack
of pragmatic guidelines for CVD prevention, treatment
and rehabilitation. To address these gaps, in this
analysis article, we present an implementation cycle for
developing, contextualising, communicating and
evaluating CVD recommendations for LMICs. This
includes a translatability scale to rank the potential ease
of implementing recommendations, prescriptions for
engaging stakeholders in implementing the
recommendations (stakeholders such as providers and
physicians, patients and the populace, policymakers
and payers) and strategies for enhancing feedback. This
approach can help LMICs combat CVD despite limited
resources, and can stimulate new implementation
science hypotheses, research, evidence and impact.
INTRODUCTION
The world is facing an enormous health dis-
parity.1 2 The largest burden of non-
communicable diseases especially cardiovas-
cular diseases (CVDs), which constitute the
leading cause of death and disability in the
world (accounting for 60% of global deaths),
is borne by low and middle income countries
(LMICs).1 2 Unlike high income countries
(HICs), LMICs lack the resources and prag-
matic solutions to tackle this crippling yet
increasing burden.1 2 In this article, we
proffer a novel implementation cycle for
identifying and implementing effective solu-
tions to combat the rising CVD burden in
the low-resource settings of LMICs, by
placing proof in pragmatism.
THE GROWING GLOBAL DISPARITY IN
CARDIOVASCULAR HEALTH
Any attempt to successfully tackle the global
burden of CVD must emphasise its effective
control in LMICs where it is a threat to
development.1 2 However, although up to
90% of the worldwide CVD burden is borne
by LMICs, they have only about 10% of the
research capacity and healthcare resources
necessary to investigate and identify sustain-
able solutions to address this escalating chal-
lenge.1–4
Moreover, proven therapies and strategies
for controlling CVD developed in HICs may
not necessarily be pragmatic for LMICs if
not adapted.3 Owing to the relative paucity
of locally conducted research, care
Key questions
What is already known about this topic?
▸ Low and middle income countries (LMICs) face
a disproportionately heavy burden of cardiovas-
cular disease (CVD) with scarce resources and
lack of pragmatic guidelines.
▸ Owing to the relative paucity of locally con-
ducted research, care providers in LMICs
seeking to practice evidence-based medicine
often attempt to directly incorporate available
practice guidelines imported from HICs.
What are the new findings?
▸ We present a novel implementation cycle for
developing, contextualising, communicating and
evaluating concise expert consensus CVD solu-
tions for LMICs.
▸ We propose a translatability scale to grade
expected ease of implementation of practice
points and recommendations especially in
resource-limited settings.
Recommendations for policy
▸ The proposed implementation cycle can help
LMICs combat CVD despite limited resources.
▸ Targeted stakeholders (players) should include
providers and physicians, patients and the popu-
lace, policymakers and payers as well as imple-
mentation partners.
▸ These ideas can stimulate new CVD implementa-
tion science hypotheses, research, evidence and
global impact.
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providers in LMICs seeking to practice evidence-based
medicine often attempt to directly incorporate avail-
able practice guidelines imported from HICs, even
though the settings, patients and resources are vastly
different (tables 1–3).3 5–7 In particular, geopolitical
and socioeconomic problems in most LMICs present
barriers to optimal CVD control. These include low
population health literacy, limited health budgets, cor-
ruption, uncoordinated health systems, unstable polit-
ical climate, faulty policies, negative influence of
certain food industries and tobacco companies, lack of
appropriate infrastructure, deficient pharmaceutical
supply chains, predominant out-of-pocket health
expenditures and barely existent health insurance
systems.3 5–9
Therefore, despite existing high-level evidence-based
guidelines from HICs and clear evidence of a declining
CVD burden in HICs,1 2 4 8 the CVD burden continues
to escalate among LMICs.1 2 4 8 The ongoing ‘parallel
CVD universes’ is akin to the situation in global polio
prevention efforts where despite the discovery of the
polio vaccine over half a century ago, new cases are still
occurring in LMICs.10 Within the socioeconomic reality
in LMICs, contextually appropriate recommendations
for CVD control need to be developed.8 9 11 12
Ideally, new direct evidence about the effectiveness of
CVD interventions in LMICs settings should be gener-
ated, but currently, LMICs do not have the wherewithal
to support CVD implementation science initiatives.3 4
Also, there are insufficient resources from HICs to
support CVD research in LMICs in a widespread and
long-term manner.3 4 13 Since the aforementioned
potential strategies to ameliorate the CVD burden in
LMICs will be either partial or long term, and presently
lives are being lost and futures blighted, intervening
action is warranted in the mean time.3 4 13
Systematic approaches are urgently needed to trans-
late the existing high-level evidence obtained in HICs
into pragmatic strategies to reduce the escalating
burden of CVD in LMICs, while gradually creating an
implementation pipeline to stimulate, absorb, process,
and disseminate new direct evidence as they accrue from
LMICs in future. This should include a new approach to
the content, packaging and delivery of evidence-based
recommendations to make them more accessible, con-
textual, and actionable, across the CVD-care continuum,
involving all stakeholders, while avoiding disease siloes,
in LMICs where the burden is heaviest (figure 1).
TRANSLATING THE CONTENT OF EVIDENCE-BASED
RECOMMENDATIONS
First, there is a need to unravel the major gaps and
needs for interventions to control CVD in LMICs along
the entire cardiovascular cascade: from ideal cardiovascu-
lar health, through emergence of CVD risk factors, to
symptomatic CVD culminating in disability and death.4
This should cover the entire intervention spectrum as
proposed in the cardiovascular disease quadrangle4 (epi-
demiological surveillance and research networks includ-
ing establishment of research agenda and priorities;
primordial, primary and secondary prevention across
Table 1 Metaphor of the ‘car’ and ‘bridge’—thrombolysis
in acute stroke17 in LMICs setting*
Stakeholders Expected roles
Populace General awareness about stroke to enable
immediate recognition of stroke and
initiation of appropriate actions.
Patient The patient/caregiver/neighbour/coworker
need to be able to recognise stroke
immediately when it occurs and act fast by
organising/initiating rapid transfer to a
centre where urgent investigations and
thrombolytic therapy can be delivered.
Providers Doctors/neurologists need to be
competent to rapidly investigate, decide
on eligibility, administer and monitor
thrombolytic therapy in patients with acute
ischemic stroke. Pharmacist: To ensure
availability of potent thrombolytic therapy
(from a genuine source, not expired,
appropriately stored and dispensed).
Policymakers To make policies that will ensure (a)
community level sensitisation about stroke
recognition and rapid action, (b) rapid
evacuation services for patients who
suffered a stroke within the therapeutic
time window and (c) availability of
proximal certified centres for rapid
evaluation and administration of
thrombolytic therapies.
Payers Health insurance companies, the
government, drug companies to work
together using the antiretroviral therapy
model to ensure accessibility of
thrombolytic therapy to LMICs using a
combination of different mechanisms:
discounts, subsidies, supplementation,
local manufacture of generic products and
donations.
Partners To ensure synergistic engagement of all
stakeholders listed above to ascertain,
evaluate and monitor implementation.
*Stroke, the clinical culmination of various cardiovascular risk
factors, is the leading cause of cardiovascular death, disability and
dementia in LMICs. It often presents in a dramatic acute/
hyperacute manner and requires urgent and appropriate action to
be taken by all stakeholders. Thrombolysis for acute ischemic
stroke is a level A class I recommendation which is proven in
HICs.10 While awaiting possible pharmacogenomic drug trials and
other new contextual evidence in LMICs, this current evidence
may be applied. The ‘car’ is the recommendation ie ‘to administer
thrombolytic therapy to all eligible patients with ischemic stroke
within the therapeutic time window’. Sections of the bridge are the
roles to be played by stakeholders without which the bridge will be
impassable and the service cannot be delivered.
HICs, high income countries; LMICs, low and middle income
countries.
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Table 2 Action should involve all stakeholders (sections of ‘the bridge’)
Stakeholders Examples of actions and roles required to control CVD
Patients Evidence-based cardiovascular health information/tips, educational materials, self-efficacy tools to be made available through novel multiple friendly
channels to patients to enable them take, seek and evaluate appropriate preventive, therapeutic and restorative actions.
Providers High-level translatable customised recommendations to be made available/accessible to clinicians, physicians, pharmacists and other medical and
paramedical personnel in LMICs using multipronged novel-friendly channels. Development of task-redistribution approaches. Training and capacity
building. This will enable them to be aware of and implement such recommendations in eligible patients.
Populace Using several novel channels, media, forums and community resources to engage the entire general populace across the lifespan about the burden,
prevention and other interventions for the entire spectrum of CVDs (Cardiovascular Cascade) from ideal cardiovascular health to cardiovascular death.
This includes population level screening for CVD and CVD risk factors and awareness campaigns in communities, schools, workplaces, places of worship,
webspace, etc. This will enable them take, seek and evaluate appropriate preventive, therapeutic and restorative actions.
Policymakers Collection and synthesis of the best available global and local evidence to produce evidence briefs for policy as the primary input into structured deliberate
dialogues with the policymakers. Engagement of all layers/grades of policymakers using novel channels. This will enable them to provide relevant
infrastructure, medications, facilities and equipment, develop evidence-based translatable policies and performance indicators and formulate policy
networks and peer-review mechanisms for policy implementation.
Payers Engagement of payers to support the implementation of high-level recommendations with relevant resources. Discounts, subsidies, supplementation, local
manufacture of generic products and donations could improve access to medications and devices.
Partners No single organisation can combat the CVD epidemic alone. It is inevitable to establish and nurture a broad-based synergistic system of collaborations
among the implementation partners including:
A. Researchers and research institutions to identify and resolve research gaps, set research agenda/priorities, along the entire cardiovascular cascade
and cardiovascular quadrangle (epidemiological surveillance; primordial/primary/secondary prevention; acute/hyperacute intervention; and
rehabilitation/reintegration).
B. Relevant national, regional and global professional bodies to engage and learn from each other and interact with other implementation partners
and stakeholders to develop and implement best interventions to combat CVDs in LMICs eg, World Hypertension League, International Society of
Hypertension, Nigerian Stroke Society, World Federation for Neurorehabilitation, National Medical Associations, American Heart Association, European
Academy of Neurology, American Society of Hypertension, European Hypertension Society, American Academy of Neurology, International Academy
Medical Panel, NICE, World Stroke Organization, World Federation of Neurology, Pan-African Society of Cardiology, Indian Stroke Association,
Chinese Society of Neurology, H3Africa CVD Consortium, societies relevant for ethical, legal social and policy-related issues as well as agricultural/
pharmaceutical sector with influence on availability of healthy food and cost-effective drugs, Global Burden of Disease expert group, the Non
Communicable Diseases Risk factor Collaboration (NCD-RiSC) consortium, etc.
C. Relevant governmental and intergovernmental agencies (to set, facilitate, implement and evaluate a global agenda for the control of CVD in
LMICs) eg, Federal and State Ministries of Health, WHO, African Union, NEPAD, European Union, European Commission, World Health Summit, G7,
G20, World Bank, African Development Bank, National Health Research Councils, United Nations, National Institute of Health (USA), NHLBI, Medical
Research Councils (UK, South Africa, etc), CIHR, ICMR, CAMS, INCMNSZ, NHMRC, Welcome Trust, and other funding agencies.
D. Relevant non-governmental organisations and private sector eg, mobile phone companies which may offer free or subsidised text messaging
platforms, film industries which may support applied theatre techniques (Bollywood, Nollywood, Hollywood, etc), philanthropic organisations (eg, Bill
Gates Foundation, Dangote Foundation, etc), pharmaceutical and medical supplies companies may provide medications and materials at lower costs
for LMICs as part of their social responsibility, print and electronic media houses: to support health awareness programmes in LMICs.
E. Advocates and ambassadors: Volunteering individuals and groups, opinion leaders, professional, faith-based, community and political leaders who
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the lifespan; hyperacute and acute care; and, rehabilita-
tion and reintegration) (see figure 1, points (A–C).4
Next, CVD practice guidelines for LMICs could be
developed (or enhanced where already available) using
solutions from the corresponding successful HIC guide-
lines which can be adapted to LMICs healthcare peculi-
arities. The focus should strictly be on high-level
recommendations (ie, class I or III evidence with level A
recommendations only) for the selected CVD
entities.3 9 11 12 However, to develop such sustainable
solutions, the multilevel barriers and facilitators of
implementing CVD guidelines in LMICs need to be fully
understood.3 9 11 12 Examples of such barriers include
socioeconomic and ecological conditions as well as soci-
etal upheavals which influenced the sustainment of
interventions in sub-Saharan Africa.3 9 11 12 Thus, gaps
and barriers in the implementation pipeline including
lack of relevant facilities, devices, medications and per-
sonnel should be taken into account while adapting the
high-level content.3 9 11 12
The complexity and nature of these barriers vary for
different interventions.3 9 11 12 While some interventions
can be implemented at home by the individual without
the need for sophisticated equipment, highly skilled
medical personnel, advanced medical infrastructures or
new legislations, others would require all of these for
implementation. Therefore, in addition to ranking solu-
tions according to classes of evidence and levels of rec-
ommendation, it is crucial to grade them in descending
order of translatability (figure 1, point (D)). A translata-
bility scale for grading solutions according to the nature
and relative complexities of barriers that need to be
navigated for their successful implementation is pro-
posed below. The proposed scale could be modified
iteratively to make it more reproducible once adopted
and in use as practical issues arise regarding its applica-
tions and implications.
Ta: Interventions that are neither limited by cost nor
personnel. In most cases they can be implemented by
individuals on their own with little or no need for
highly skilled personnel, medications, expensive appli-
ances or sophisticated infrastructure (eg, increased
physical activity,14 dietary salt reduction,15 healthy
dietary choices).
Tb: Interventions limited mainly by cost/availability/
affordability only with little or no need for intense
continuous care or supervision by highly skilled per-
sonnel (eg, medications8 9 that can be administered
once correctly prescribed and safe for the individual
patient eg, oral antiplatelet to prevent stroke).
Tc: Interventions limited mainly by the absence of
expert personnel and facility only but not cost (eg,
speech therapy:16 when the potential beneficiaries are
able to afford but not access the service due to the
absence of speech therapist and/or gadgets required
for same).
Td: Interventions limited by both personnel, and cost
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Table 3 Evidence for the missing links in existing cardiovascular diseases guidelines for low and middle income countries:
the diabetes mellitus scenario from three continents
Country/region Malaysia/Asia Brazil/South America South Africa/Africa
Publication details
Year 2015 2010 2012
Title Management of type 2 diabetes
mellitus (5th edition)6
Algorithm for the treatment of
type 2 diabetes: a position
statement of Brazilian Diabetes
Society5
The 2012 SEMDSA guideline for
the management of type 2
diabetes (revised)7









EASD algorithm. Joslin Diabetes
Center
Update literature and the
Department of Health’s draft type















Methods in detail Members of the task force were
assigned topics. Articles
retrieved were graded. Draft
guideline was posted on the
Malaysian Endocrine and
Metabolic Society, Ministry of
Health Malaysia websites for
comment and feedback.
Guideline presented to the
Technical Advisory Committee
and the Health Technology
Assessment and Clinical
Practice Guidelines Council,
Ministry of Health for review and
approval.
Brazilian Diabetes Society
obtained opinions of a panel of
renowned Brazilian specialist
about recommendations and
controversial arguments on the
treatment of T2DM in
international literature.
Arguments were presented to the
panel with each member scoring
each argument on a Likert scale.
Broad topic of management was
divided into smaller sections and
allocated to experts to lead.
Information on each section was
presented to the general
committee and amendments and
additions suggested best on ‘best
practice’.
Clinical issues addressed (components of the cardiovascular quadrangle)
Primordial prevention No No Yes
Pre-diabetes No No No
Age-specific treatment No No Yes
Nutrition Yes No Yes
Exercise Yes No Yes
Acute care/emergencies Yes No Yes
Conventional care Yes No No
Rehabilitation No No No
Target population (the 6Ps)
Physicians Yes NS Yes
Nurses Yes NS Yes
Primary caregivers Yes NS Yes
Pharmacist Yes NS No
Dieticians Yes NS Yes
Policymakers No NS Yes
Payers No NS Yes
Continued




 on June 15, 2021 at T










ealth: first published as 10.1136/bm





While determining translatability, ethical, legal, socio-
cultural and economic (ELSE) factors should be consid-
ered (figure 1, point D) in addition to other barriers
and facilitators. Just telling an individual patient to
reduce alcohol use may be difficult although cheap.
However, if the guidelines consider the sociocultural
uniqueness of the country, then allocation can be made
for family or religious input. Use of translatability
weighting gives every healthcare provider a recommen-
dation to work with irrespective of their cadre. There is
nothing to be gained in forcing the latest thrombolytic
therapy down the throats of a health extension worker
in an African village when he/she is never going to be
able to get it done. Why not just ensure that they at least
follow proven Ta practices for CVD prevention and
treatment?
However, while Ta preventive interventions such as
increasing physical activity and modifying diet are highly
cost-effective ultimately, implementing them at scale in a
population may require significant expenditure initially.
Their implementation may also be hindered by difficulty
in changing entrenched behaviours at the individual
and population levels particularly as they may require
changing norms to prevent an invisible problem without
immediately obvious benefits. For instance, individuals
may not immediately realise that unhealthy diet and sed-
entary lifestyle can lead to atherosclerosis, stroke and
premature death. So the challenge is in making the con-
sequences of sedentary lifestyle and unhealthy diet
obvious and communicating the effectiveness and basis
of the required change at the population and personal
level. This may include funding of mass educational pro-
grammes needed to motivate change and provision of
an enabling environment to make the change possible
and sustainable. Social capital can be provided through
family and social activities such as ‘walk for life’ exercise
programmes integrated into the routine activities by
community, professional and religious groups.
Nevertheless, adopting the translatability scale can
encourage the discovery, development, prioritisation and
adoption of highly effective adaptable Ta recommenda-
tions which can perhaps be more easily implemented by
all stakeholders in LMICs. It can also promote imple-
mentation science research for the modification of bar-
riers and facilitators for the translation of Td
recommendations in order to elevate them towards Ta
status.
The implementation of complex interventions in
primary care is influenced by the evidence of benefit,
ease of use and adaptation to local circumstances.12
Identifying and overcoming the causes of the
evidence-to-practice gap and improving the translatabil-
ity and ‘fit’ between intervention and context is critical
in determining the success of implementation.12 The
current scenario presents a unique opportunity to
develop and implement Ta solutions and recommenda-
tions in LMICs. In addition, implementing such high
level Ta recommendations in LMICs can provide insights
for implementation in HICs. These considerations can
inform the development of pragmatically weighted
recommendations in the form of guidelines, practice
points, statements, health tips and messages on CVD
which are packaged and tailored to all specific audi-
ences (tables 1 and 2).
Examining existing LMICs CVD guidelines through
the lens of the implementation cycle reveals gaps in
their development and content (figure 1, points (A–
D)). This is illustrated by three type 2 diabetes mellitus
Table 3 Continued
Clinical issues addressed (components of the cardiovascular quadrangle)
Paramedics No NS No
Patients and populace No NS No
Implementation partners No No No
Other considerations (including translatability and ELSE)
Translatability rating No No No
Ethical No No No
Legal No No No
Social Yes No No
Psychological Yes No No
Economic No No No
Comorbidity Yes No Yes
Quality indicator Yes Yes No
Dissemination channels No No No
Surveillance No No No
Renewal date 2019 NS NS
ADA, American Diabetes Association; EASD, European Association for the Study of Diabetes; ELSE, ethical, legal, sociocultural and
economic; NS, not stated; SEMDSA, Society for Endocrinology, Metabolism and Diabetes of South Africa; T2DM, type 2 diabetes mellitus.
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guidelines from LMICs in three continents5–7 (table 3).
Apart from weaknesses in the content (such as lack of
adequate and systematic considerations of translatability,
ethical, legal, socioeconomic implications), appropriate
user-friendly dissemination channels to target audiences
were not clearly articulated.5–7
ENGAGING STAKEHOLDERS IN THE DELIVERY OF
RECOMMENDATIONS
Bulky consensus guidelines published by many profes-
sional bodies in academic journals to increase health-
care providers’ awareness of evidence-based approaches
to disease management have often neither percolated
down to the stakeholders nor produced the desired
results.18 Dissemination of high-level CVD recommenda-
tions in LMICs, therefore, must be transformed and
combined with effective implementation strategies to
drastically improve the knowledge, attitude, behaviour
and practice of all stakeholders and foster an enabling
implementation environment so as to produce and
sustain the desired effects (tables 1 and 2).
Hitherto, attention has been focused solely on ‘the car’
(the evidence-based recommendation) to the exclusion of
‘the bridge’ (the stakeholders) over which the car must ply
in order to deliver the care and desired outcomes (figure 1
and table 1).17 For example, the timely delivery of
thrombolytic therapy to eligible patients who suffered a
stroke17 requires the coordinated actions of all stakeholders
including the patient, caregiver and all other players in the
health sector.19 Therefore, in LMICs, there is a need for
contextualisation (targeted packaging) of solutions and their
dissemination through novel cost-effective multidirectional
interactive channels to mobilise every stakeholder so as to
foster ownership by all. This is in line with the recognition
of community ownership and mobilisation as crucial
Figure 1 Pragmatic guideline development and implementation cycle. Points D–G are often neglected in existing guidelines.
Low and middle income countries (LMICs)-specific cardiovascular disease (CVD) expert consensus guidelines that incorporate
available strictly high-level scientific evidence along with pragmatic recommendations for how to implement these proven
therapies using contextually relevant methods in LMICs, and effectively communicated via the already widely available interactive
channels (like mobile phones) to all stakeholders, could do away with the multilevel barriers and go a long way in stemming the
rising CVD burden in LMICs.
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facilitators for intervention sustainability, both early on and
after intervention implementation by many of the 41
studies (1996–2015) in a systematic review of empirical lit-
erature to explore how health interventions implemented
in sub-Saharan Africa are sustained.9 These findings
further support the recommendation of contextualisation
and targeted packaging of solutions to all relevant specific
audiences in the implementation cycle.12 Considerations
for contextualisation should include factors related to each
of the 6Ps (tables 1 and 2 and figure 1) including external
contextual factors (policies, incentivisation structures,
dominant paradigms, stakeholders’ buy-in, infrastructure
and advances in technology), organisation-related factors
(culture, available resources, integration with existing pro-
cesses, relationships, skill mix and staff involvement) and
individual professional factors (professional role, under-
lying philosophy of care and competencies).12
Apart from gaps in contextualisation, the communica-
tion of solutions to targeted audiences through appro-
priate channels is often deficient (figure 1, point (F)).20
For instance, in a survey of 485 UK-based principal inves-
tigators of publicly funded applied and public health
research, less than one-third stated that they would
produce key messages for specific audiences.20 This is
despite the fact that most respondents indicated that
part of their dissemination plan involved targeting spe-
cific audiences (such as policymakers, service managers
or general practitioners).20 Although researchers recog-
nise the importance of disseminating the findings of
their work, they are focused on academic publications
and the few who apply a range of dissemination chan-
nels do so in an uncoordinated fashion.20
This critical communication gap must be addressed
comprehensively. Therefore, although it is not clear
which channels work best,20 we propose communication
cycles and circles to disseminate targeted key messages
through multiple channels including social media, text
messaging platforms, mobile phone apps, applied
theatre arts, websites, mobile health platforms, elec-
tronic media, print media, dedicated forums and moni-
toring software/dashboards. This will enable researchers
to interactively and continuously engage with all stake-
holders; such as providers (personnel–clinicians,
healthcare workers), policymakers, patients, populace
(communities), partners and payers (table 2 and figure
1, points (E and F)).9 20 The right combinations of
channels can be selected based on the preferences of
the target audiences and accruing evidence.
ENHANCING FEEDBACK BY HARMONISING OUTCOME
MEASURES
The effectiveness of the entire implementation process
and dissemination channels should be evaluated using
appropriate measures. Although it is known that imple-
mentation will greatly benefit from easy-to-apply, harmo-
nised and rigorous outcome measures; reviews suggest
that less than half of the existing measures are
psychometrically validated (ie, in many cases, no data
exists on whether the measure assesses the construct it is
intended to address).21 Other challenges include the dif-
ficulties in applying such measures in routine clinical
practice settings, and the dearth of measures available
for certain implementation constructs (eg, context and
adaptation).21 Furthermore, the use of different
outcome measures by similar studies prevents the inte-
gration of results across such studies.21
It is therefore crucial for implementation partners
(table 2 and figure 1) to develop and use simple and effect-
ive harmonised outcome measures and performance indicators to
monitor and evaluate implementation progress along the
four axes of the cardiovascular quadrangle. For example,
reducing the burden of stroke will require the monitor-
ing of stroke surveillance, prevention, acute care and
rehabilitation services. Enhancing the quality of such
feedback will facilitate the identification of evidence gaps
and implementation barriers, which can in turn lead to
new research studies (figure 1, points (A, B and G) and
yield better evidence and recommendations.
This will potentially fast-track integrated knowledge
translation driven by collaboration between researchers
and decision-makers.22 Patients and service leaders can
help researchers to clarify goals, gather new evidence in
real-life complex systems, and identify appropriate
approaches for conducting and evaluating planned
changes.23 Such evaluations may be formative, using
findings to optimise implementation, or summative, pro-
ducing evidence of ultimate impact or both. In any case,
careful thought is needed to protect the integrity of eva-
luations and feedback.23
CONCLUSION
Practice guidelines are developed based on the strength
of available evidence.18 However, the reality is that most
of the strong evidence stem from clinical trials which
usually test ‘one thing at a time’, and not necessarily
how complex systems operate.3 9 11 12 Ironically,
although the recommendations are often published in
high-impact visible journals, they are often poorly con-
textualised and communicated and so do not percolate
down to key stakeholders,18 and their implementation
remains a challenge, particularly in LMICs.13 18 We
therefore propose an implementation cycle which addresses
hitherto missing links in CVD solutions. It includes strat-
egies for generating new evidence in real-life complex
ecosystems and implementation environment, and pro-
cesses for content development, contextualisation, com-
munication and feedback (figure 1). This pathway can
incrementally stimulate, monitor, absorb and process the
accruing evidence from researchers and consortia exam-
ining CVDs in LMICs while motivating all stakeholders
and creating enabling environment for the implementa-
tion of existing evidence-based solutions. Holistic deploy-
ment of this cycle, placing proof in pragmatism, can
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revolutionise our capacity to tame the burden of CVDs
in LMICs despite limited resources.
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